HEK293/Human FFA1(GPR40) Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0093A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Free fatty acid receptor 1 (FFA1), also known as GPR40, is a G protein-coupled receptor activated by medium- and long-chain free fatty acids. It is primarily distributed in pancreatic β-cells, intestinal enteroendocrine L cells, as well as the central nervous system and taste buds in humans. Functioning as a key nutrient sensor, its core role is to detect dietary fatty acid intake and, by coupling to Gq protein signaling pathways, potently stimulate glucose-dependent insulin secretion when blood glucose levels rise, which is vital for maintaining glucose homeostasis. Consequently, FFA1 is regarded as a highly promising therapeutic target for type 2 diabetes, aiming to restore its physiological insulin-secreting function, and related agonist drugs have advanced into clinical trials.
Screeningbio’s HEK293/Human FFA1 (GPR40) cell line overexpress FFAR1 and is designed to detect increases in intracellular IP-1 levels in response to agonist stimulation of the receptor. Cisbio HTRF IP-1 kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | FFAR1 |
Accession Number | NM_005303 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
Free fatty acid receptor 1 (FFA1), also known as GPR40, is a G protein-coupled receptor activated by medium- and long-chain free fatty acids. It is primarily distributed in pancreatic β-cells, intestinal enteroendocrine L cells, as well as the central nervous system and taste buds in humans.
Functioning as a key nutrient sensor, its core role is to detect dietary fatty acid intake and, by coupling to Gq protein signaling pathways, potently stimulate glucose-dependent insulin secretion when blood glucose levels rise, which is vital for maintaining glucose homeostasis.
Consequently, FFA1 is regarded as a highly promising therapeutic target for type 2 diabetes, aiming to restore its physiological insulin-secreting function, and related agonist drugs have advanced into clinical trials.